The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
The 3rd Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting. Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode.
This year’s event in Vienna will bring together the “who’s who” from the biotech, pharma and finance segments to allow delegates to meet more key decision makers in three days of partnering meetings than they could in a whole year.
Join us in Philadelphia, PA, June 3-6, 2019 as more than 16,000 attendees from around the globe gather for unparalleled partnering, education, networking, and to see all that tri-state area has to offer. The region's vast array of leading universities and research institutions fosters a collaborative environment.
The Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to present the Fifth International Cancer lmmunotherapy Conference.
The program will focus on "Translating Science into Survival," and feature talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.
Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.
Europe’s Leading Biopartnering and Investment Conference
BioTrinity, now in its 13th year, is Europe’s leading Biopartnering and Investment conference, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
Dr. Michael Stein, CEO of Valo Therapeutics, is a business leader and strategic adviser with C-suite experience in healthcare. Immediately prior to his appointment, Michael was the founding CEO of OxStem Ltd, an award-winning biotechnology spin-out from the University of Oxford, which broke the UK record for a seed round fund-raise of over £16m in May 2016.
The 5th annual LSX World Congress is the new name for the Biotech and Money / Medtech and Money World Congress. The name may have changed, but it retains its core offering for the C-suite of the global life science industry.
The LSX World Congress is a high-calibre, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses.
Leena Ylösmäki, Post-doctoral Research Associate, has over 15 years of experience in the fields of basic and applied virology and cancer research. During her academic career, she has studied various different viruses including Influenza A, vaccinia and adenoviruses. Before joining Valo Therapeutics, Leena worked as a PhD researcher at the university of Helsinki where she designed and developed various oncolytic viruses for cancer immunotherapy.